[
    [
        {
            "time": "",
            "original_text": "沃森生物：吸附无细胞百白破联合疫苗年产能超1000万剂",
            "features": {
                "keywords": [
                    "沃森生物",
                    "吸附无细胞百白破联合疫苗",
                    "年产能",
                    "1000万剂"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "沃森生物：吸附无细胞百白破联合疫苗年产能超1000万剂",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "[推荐评级] 沃森生物(300142)半年报点评：上半年业绩扭亏 静待PCV13上市带动业绩爆发",
            "features": {
                "keywords": [
                    "沃森生物",
                    "半年报",
                    "扭亏",
                    "PCV13",
                    "业绩爆发"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[推荐评级] 沃森生物(300142)半年报点评：上半年业绩扭亏 静待PCV13上市带动业绩爆发",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[增持评级] 深度*公司*沃森生物(300142)中报点评：2018H1扭亏为盈 静待PCV13获批",
            "features": {
                "keywords": [
                    "沃森生物",
                    "中报",
                    "扭亏为盈",
                    "PCV13",
                    "获批"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[增持评级] 深度*公司*沃森生物(300142)中报点评：2018H1扭亏为盈 静待PCV13获批",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        }
    ]
]